GENMAB A/S
No SEC Form 4 filings for $GMAB in the last 30 days.
See all $GMAB insider activity →Genmab (GMAB) shares rose about 4.4% after the company reported first-half revenue up 25% to $2.05B, driven by royalty revenue up 24% to $1.71B. Management raised full-year revenue guidance to $4.325B-$4.525B and adjusted operating profit to $1.225B. Royalty strength was linked to Darzalex and Kesimpta, according to the article.
European shares rose slightly, led by healthcare, as investors weighed higher oil prices and renewed Middle East tensions ahead of the U.S. jobs report. The STOXX 600 gained 0.2%. Brent rose to about $83.29. Munich Re shares fell 3.7% despite higher Q2 net profit. Genmab rose 7.2% after higher first-half revenue and a raised full-year outlook.
Genmab’s Q2 2026 earnings call set full-year 2026 revenue guidance at $4.3 billion to $4.5 billion and operating profit at $1.1 billion to $1.4 billion. DARZALEX net trade sales were $4,207 million in Q2, with EPKINLY H1 sales $312 million and proprietary portfolio revenue $396 million. Management cited Merus integration, a 3.6% effective tax rate, and multiple late-2026 readouts.
Over the past 7 days, alphai's AI scored 4 news stories mentioning GMAB (GENMAB A/S). Coverage has skewed bullish: 4 bullish, 0 neutral, and 0 bearish.
Recent GMAB coverage spans earnings, technology and financial news.
Raised guidance tied to accelerating royalty receipts from Darzalex and Kesimpta, offset by higher operating expenses for Rina-S and petosemtamab.
Raised full-year outlook and stronger H1 revenue are likely to support near-term momentum and re-rate expectations.
Guidance upside plus multiple late-stage readout catalysts (EPKINLY, petosemtamab, Rina-S) increases near-to-mid term visibility for revenue and margin trajectory.
The interim results and revised full-year guidance are a direct fundamental catalyst for GMAB, with upside risk tied to royalty growth and pipeline execution.
The EPCORE DLBCL-1 overall survival miss is a negative clinical read-across for epcoritamab, increasing uncertainty around near-term valuation support.
alphai scores every news story that mentions GMAB with an AI model for sentiment and relevance, and aggregates insider trades from GENMAB A/S's SEC EDGAR Form 4 filings. Figures refresh continuously.
Genmab (GMAB) shares rose about 4.4% after the company reported first-half revenue up 25% to $2.05B, driven by royalty revenue up 24% to $1.71B. Management raised full-year revenue guidance to $4.325B-$4.525B and adjusted operating profit to $1.225B. Royalty strength was linked to Darzalex and Kesimpta, according to the article.
4 min readEuropean shares rose slightly, led by healthcare, as investors weighed higher oil prices and renewed Middle East tensions ahead of the U.S. jobs report. The STOXX 600 gained 0.2%. Brent rose to about $83.29. Munich Re shares fell 3.7% despite higher Q2 net profit. Genmab rose 7.2% after higher first-half revenue and a raised full-year outlook.
4 min readGenmab’s Q2 2026 earnings call set full-year 2026 revenue guidance at $4.3 billion to $4.5 billion and operating profit at $1.1 billion to $1.4 billion. DARZALEX net trade sales were $4,207 million in Q2, with EPKINLY H1 sales $312 million and proprietary portfolio revenue $396 million. Management cited Merus integration, a 3.6% effective tax rate, and multiple late-2026 readouts.
6 min readGenmab reported first-half 2026 revenue of $2,051 million, up 25% from $1,640 million a year earlier, driven by higher DARZALEX and Kesimpta royalties and higher EPKINLY net product sales. Royalty revenue rose to $1,708 million. Genmab updated 2026 guidance, citing higher DARZALEX royalties and EPKINLY net sales, and noted positive Phase 3 data for epcoritamab plus lenalidomide.
7 min readSimply Wall St reports Genmab and partner AbbVie said the Phase 3 EPCORE DLBCL-1 trial of epcoritamab did not meet its overall survival primary endpoint in the US. The article cites Genmab’s DKK1,858.5 share price and a fair value estimate of DKK2,392.08, implying about 22% upside, and flags risks including Darzalex patent expiry and upcoming Epkinly results.
6 min readIntel reported Q2 results above Wall Street expectations and raised its 2026 capital expenditures outlook. Deckers Outdoor lifted its profit outlook and reported higher Q1 sales. Edwards Lifesciences posted double-digit Q2 revenue growth and raised the low end of guidance. Genmab and AbbVie’s lymphoma drug missed a Phase 3 primary endpoint.
2 min readGenmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) clarified primary endpoints from their Phase 3 EPCORE DLBCL-1 trial of epcoritamab (DuoBody-CD3xCD20) in relapsed or refractory DLBCL. The study compares subcutaneous epcoritamab monotherapy versus investigator’s choice chemoimmunotherapy (R-GemOx or BR) in adults ineligible for autologous stem cell transplant. Topline results were announced Jan 16, 2026.
2 min readGenmab (GMAB) and AbbVie (ABBV) clarified that in the U.S. portion of the Phase 3 EPCORE DLBCL-1 trial of epcoritamab (Epcoritamab) for relapsed/refractory DLBCL, overall survival (OS) was the sole primary endpoint and was not met. The trial compares epcoritamab vs investigator’s choice chemotherapy. Results will be submitted for publication.
4 min readGenmab (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) clarified Phase 3 EPCORE DLBCL-1 epcoritamab results. In the U.S., overall survival (OS) was the sole primary endpoint and was not met versus investigator’s choice chemoimmunotherapy (R-GemOx or BR) in relapsed/refractory DLBCL ineligible for transplant. Additional results will be submitted for publication.
4 min readGenmab A/S (Nasdaq: GMAB) said worldwide net trade sales of DARZALEX (daratumumab), including the subcutaneous DARZALEX FASPRO, were $4,207 million in Q2 2026, with $2,435 million in the U.S. and $1,772 million in other regions, as reported by Johnson & Johnson (Janssen). Genmab earns royalties on worldwide net sales under its license to J&J.
2 min read
